2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|December 19, 2013
Pfizer Appoints Head of Vaccines
Author(s)Pharmaceutical Technology Editors
Pfizer appoints management changes to take effect in 2014.
Advertisement
Doug Lankler, who was to become general counsel on January 1, and Rady Johnson who was to become chief compliance and risk officer on January 1, both assume their new positions immediately.
On January 1, the company will begin operating with three commercial businesses-the Global Innovative Pharmaceutical business, led by Geno Germano, the Global Established Pharmaceutical business, led by John Young, and the Vaccines, Oncology, and Consumer Healthcare business led by Albert Bourla.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement